HRP20110845T1 - Antitumorski dihidropiran-2-onski spojevi - Google Patents
Antitumorski dihidropiran-2-onski spojevi Download PDFInfo
- Publication number
- HRP20110845T1 HRP20110845T1 HR20110845T HRP20110845T HRP20110845T1 HR P20110845 T1 HRP20110845 T1 HR P20110845T1 HR 20110845 T HR20110845 T HR 20110845T HR P20110845 T HRP20110845 T HR P20110845T HR P20110845 T1 HRP20110845 T1 HR P20110845T1
- Authority
- HR
- Croatia
- Prior art keywords
- image
- tautomer
- pharmaceutically acceptable
- stereoisomer
- acceptable salt
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract 44
- 230000000259 anti-tumor effect Effects 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 23
- 239000001257 hydrogen Substances 0.000 claims abstract 23
- 125000006710 (C2-C12) alkenyl group Chemical group 0.000 claims abstract 8
- 125000006711 (C2-C12) alkynyl group Chemical group 0.000 claims abstract 6
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract 5
- 229910003827 NRaRb Inorganic materials 0.000 claims abstract 4
- 125000000217 alkyl group Chemical group 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims 42
- 150000002431 hydrogen Chemical class 0.000 claims 13
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 241000689227 Cora <basidiomycete fungus> Species 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
- C07D309/38—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms one oxygen atom in position 2 or 4, e.g. pyrones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrane Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
Spoj opće formule I,naznačen time, što se R1 bira između vodika, ORa, OCORa, OCOORa, NRaRb, NRaCORb i NRaC(NRa)NRaRb;R2 i R3 se svaki nezavisno biraju između vodika, supstituiranog ili nesupstituiranog C1-C12 alkila, supstituiranog ili nesupstituiranog C2-C12 alkenila i supstituiranog ili nesupstituiranog C2-C12 alkinila; R41, R42, R43, R44, R45, R46, R47 i R48 se svaki nezavisno biraju između vodika, supstituiranog ili nesupstituiranog
Claims (42)
1. Spoj opće formule I
[image]
,
naznačen time, što se R1 bira između vodika, ORa, OCORa, OCOORa, NRaRb, NRaCORb i NRaC(NRa)NRaRb;
R2 i R3 se svaki nezavisno biraju između vodika, supstituiranog ili nesupstituiranog C1-C12 alkila, supstituiranog ili nesupstituiranog C2-C12 alkenila i supstituiranog ili nesupstituiranog C2-C12 alkinila;
R41, R42, R43, R44, R45, R46, R47 i R48 se svaki nezavisno biraju između vodika, supstituiranog ili nesupstituiranog C1-C12 alkila, supstituiranog ili nesupstituiranog C2-C12 alkenila i supstituiranog ili nesupstituiranog C2-C12 alkinila;
R5, R6 i R7 se svaki nezavisno biraju između vodika, CORa, COORa, supstituiranog ili nesupstituiranog C1-C12 alkila, supstituiranog ili nesupstituiranog C2-C12 alkenila i supstituiranog ili nesupstituiranog C2-C12 alkinila, ili R5 i R48 zajedno sa odgovarajućim N atomom i C atomom za koje su pričvršćeni mogu formirati supstituiranu ili nesupstituiranu heterocikličnu grupu;
Ra i Rb se svaki nezavisno biraju između vodika, supstituiranog ili nesupstituiranog C2-C12alkila, supstituiranog ili nesupstituiranog C2-C12 alkenila, supstituiranog ili nesupstituiranog C2-C12 alkinila, supstituiranog ili nesupstituiranog arila i supstituirane ili nesupstituirane heterociklične grupe; i
svaka isprekidana linija predstavlja opcijsku dodatnu vezu;
ili je njegova farmaceutski prihvatljiva sol, tautomer ili stereoizomer.
2. Spoj prema zahtjevu 1 koji ima slijedeću formulu II
[image]
,
naznačen time, što su R1, R41, R43 i R48, R5, R6 i R7 kako je definirano u zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, tautomer ili stereoizomer.
3. Spoj prema zahtjevu 1, naznačen time, što se R2 i R3 svaki nezavisno biraju između vodika i supstituiranog ili nesupstituiranog C1-C6 alkila, ili njegova farmaceutski prihvatljiva sol, tautomer ili stereoizomer.
4. Spoj prema zahtjevu 3, naznačen time, što su R2 i R3 vodik, ili njegova farmaceutski prihvatljiva sol, tautomer ili stereoizomer.
5. Spoj prema bilo kojem od prethodnih zahtjeva, naznačen time, što se R1 bira između vodika, ORa i OCORa, pri čemu se Ra bira između vodika i supstituiranog ili nesupstituiranog C1-C6 alkila, ili njegova farmaceutski prihvatljiva sol, tautomer ili stereoizomer.
6. Spoj prema zahtjevu 5, naznačen time, što je R1 vodik ili metoksi, ili njegova farmaceutski prihvatljiva sol, tautomer ili stereoizomer.
7. Spoj prema bilo kojem od zahtjeva 1 i 3-6, naznačen time, što se grupe R42, R44, R45, R46 i R47 nezavisno biraju između vodika i supstituiranog ili nesupstituiranog C1-C6 alkila, ili njegova farmaceutski prihvatljiva sol, tautomer ili stereoizomer.
8. Spoj prema zahtjevu 7, naznačen time, što se grupe R42, R44, R45, R46, R47 nezavisno biraju između vodika, supstituiranog ili nesupstituiranog metila, supstituiranog ili nesupstituiranog izopropila i supstituiranog ili nesupstituiranog tertbutila, ili njegove farmaceutski prihvatljive soli, tautomera ili stereoizomera.
9. Spoj prema zahtjevu 8, naznačen time, što su R42, R44, R45, R46 i R47 vodik, ili njegova farmaceutski prihvatljiva sol, tautomer ili stereoizomer.
10. Spoj prema bilo kojem od prethodnih zahtjeva, naznačen time, što se grupe R41, R43 i R48 nezavisno biraju između vodika i supstituiranog ili nesupstituiranog C1-C6 alkila, ili njegova farmaceutski prihvatljiva sol, tautomer ili stereoizomer.
11. Spoj prema zahtjevu 10, naznačen time, što se grupe R41, R43 i R48 nezavisno biraju između vodika, supstituiranog ili nesupstituiranog metila, supstituiranog ili nesupstituiranog izopropila i supstituiranog ili nesupstituiranog tert-butila, ili njegova farmaceutski prihvatljiva sol, tautomer ili stereoizomer.
12. Spoj prema zahtjevu 11, naznačen time, što su R41 i R43 metil, ili njegova farmaceutski prihvatljiva sol, tautomer ili stereoizomer.
13. Spoj prema zahtjevu 11 ili 12, naznačen time, što se R48 bira između izopropila, tert-butila i benzila, ili njegova farmaceutski prihvatljiva sol, tautomer ili stereoizomer.
14. Spoj prema bilo kojem od prethodnih zahtjeva, naznačen time, što se R5 i R6 svaki nezavisno biraju iz grupe koja sadrži vodik i supstituirani ili nesupstituirani C1-C6 alkil, ili njegova farmaceutski prihvatljiva sol, tautomer ili stereoizomer.
15. Spoj prema zahtjevu 14, naznačen time, što su R5 i R6 vodik, ili njegova farmaceutski prihvatljiva sol, tautomer ili stereoizomer.
16. Spoj prema bilo kojem od prethodnih zahtjeva, naznačen time, što se R7 bira između vodika, supstituiranog ili nesupstituiranog C1-C12 alkila i supstituiranog ili nesupstituiranog C2-C12 alkenila, ili njegova farmaceutski prihvatljiva sol, tautomer ili stereoizomer.
17. Spoj prema zahtjevu 16, naznačen time, što se R7 bira između vodika i supstituiranog C2-C12 alkenila, ili njegova farmaceutski prihvatljiva sol, tautomer ili stereoizomer.
18. Spoj prema zahtjevu 17, naznačen time, što je R7 alkenil grupa koja je supstituirana na jednoj ili više pozicija halogenom, OR’, =O, OCOR’, OCONHR’, OCON(R’)2 i protektiranom OH, pri čemu se svaka od R’ grupa nezavisno bira između vodika, supstituiranog ili nesupstituiranog C1-C12 alkila, supstituiranog ili nesupstituiranog C2-C12 alkenila, supstituiranog ili nesupstituiranog C2-C12 alkinila i supstituiranog ili nesupstituiranog arila, ili njegova farmaceutski prihvatljiva sol, tautomer ili stereoizomer.
19. Spoj prema bilo kojem od prethodnih zahtjeva, naznačen time, što je dodatna veza prisutna na svim mjestima označenim točkastom linijom, ili njegova farmaceutski prihvatljiva sol, tautomer ili stereoizomer.
20. Spoj prema zahtjevu 1 ili 2, naznačen time, što ima slijedeću formulu
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
ili njegovu farmaceutski prihvatljivu sol, tautomer ili stereoizomer.
21. Spoj prema zahtjevu 1 ili 2, naznačen time, što ima slijedeću formulu
[image]
ili njegova farmaceutski prihvatljiva sol, tautomer ili stereoizomer.
22. Spoj prema zahtjevu 1 ili 2, naznačen time, što ima slijedeću formulu
[image]
ili njegova farmaceutski prihvatljiva sol, tautomer ili stereoizomer.
23. Spoj prema zahtjevu 1 ili 2, naznačen time, što ima slijedeću formulu
[image]
ili njegova farmaceutski prihvatljiva sol, tautomer ili stereoizomer.
24. Spoj prema zahtjevu 1 ili 2, naznačen time, što ima slijedeću formulu
[image]
ili njegova farmaceutski prihvatljiva sol, tautomer ili stereoizomer.
25. Spoj prema zahtjevu 1 ili 2, naznačen time, što ima slijedeću formulu
[image]
ili njegova farmaceutski prihvatljiva sol, tautomer ili stereoizomer.
26. Spoj prema zahtjevu 1 ili 2, naznačen time, što ima slijedeću formulu
[image]
ili njegova farmaceutski prihvatljiva sol, tautomer ili stereoizomer.
27. Spoj prema zahtjevu 1 ili 2, naznačen time, što ima slijedeću formulu
[image]
ili njegova farmaceutski prihvatljiva sol, tautomer ili stereoizomer.
28. Spoj prema zahtjevu 1 ili 2, naznačen time, što ima slijedeću formulu
[image]
ili njegova farmaceutski prihvatljiva sol, tautomer ili stereoizomer.
29. Spoj prema zahtjevu 1 ili 2, naznačen time, što ima slijedeću formulu
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
ili je njegova farmaceutski prihvatljiva sol, tautomer ili stereoizomer.
30. Spoj prema zahtjevu 1 ili 2, naznačen time, što ima slijedeću formulu
[image]
ili njegova farmaceutski prihvatljiva sol, tautomer ili stereoizomer.
31. Spoj prema zahtjevu 1 ili 2, naznačen time, što ima slijedeću formulu
[image]
ili njegova farmaceutski prihvatljiva sol, tautomer ili stereoizomer.
32. Spoj prema zahtjevu 1 ili 2, naznačen time, što ima slijedeću formulu
[image]
ili njegova farmaceutski prihvatljiva sol, tautomer ili stereoizomer.
33. Spoj prema zahtjevu 1 ili 2, naznačen time, što ima slijedeću formulu
[image]
ili njegova farmaceutski prihvatljiva sol, tautomer ili stereoizomer.
34. Spoj prema zahtjevu 1 ili 2, naznačen time, što ima slijedeću formulu
[image]
ili njegova farmaceutski prihvatljiva sol, tautomer ili stereoizomer.
35. Spoj prema zahtjevu 1 ili 2, naznačen time, što ima slijedeću formulu
[image]
ili njegova farmaceutski prihvatljiva sol, tautomer ili stereoizomer.
36. Spoj prema zahtjevu 1 ili 2, naznačen time, što ima slijedeću formulu
[image]
ili njegova farmaceutski prihvatljiva sol, tautomer ili stereoizomer.
37. Spoj prema zahtjevu 1 ili 2, naznačen time, što ima slijedeću formulu
[image]
ili njegova farmaceutski prihvatljiva sol, tautomer ili stereoizomer.
38. Spoj prema zahtjevu 1 ili 2, naznačen time, što ima slijedeću formulu
[image]
ili njegova farmaceutski prihvatljiva sol, tautomer ili stereoizomer.
39. Farmaceutska smjesa, naznačena time, što sadrži spoj prema bilo kojem od prethodnih zahtjeva, ili njegovu farmaceutski prihvatljivu sol, tautomer ili stereoizomer, i farmaceutski prihvatljivi razblaživač ili nosač.
40. Spoj prema bilo kojem od zahtjeva 1 do 39, ili njegova farmaceutski prihvatljiva sol, tautomer ili stereoizomer, naznačeni time, što se koriste kao lijek.
41. Spoj ili smjesa prema bilo kojem od zahtjeva 1 do 39, ili njegova farmaceutski prihvatljiva sol, tautomer ili stereoizomer, naznačeni time, što se koriste za liječenje kancera.
42. Upotreba spoja ili smjese prema bilo kojem od zahtjeva 1 do 39, ili njegove farmaceutski prihvatljive soli, tautomera ili stereoizomera, naznačeni time, što se koriste u izradi lijeka za liječenje kancera.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06380173 | 2006-06-16 | ||
| PCT/EP2007/055959 WO2007144423A1 (en) | 2006-06-16 | 2007-06-15 | Antitumoral dihydropyran-2-one compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110845T1 true HRP20110845T1 (hr) | 2011-12-31 |
Family
ID=38508885
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110845T HRP20110845T1 (hr) | 2006-06-16 | 2011-11-14 | Antitumorski dihidropiran-2-onski spojevi |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US8324406B2 (hr) |
| EP (3) | EP2404913A3 (hr) |
| JP (2) | JP5117491B2 (hr) |
| KR (1) | KR101474031B1 (hr) |
| CN (2) | CN102336730A (hr) |
| AR (1) | AR061506A1 (hr) |
| AT (1) | ATE522514T1 (hr) |
| AU (1) | AU2007259257B8 (hr) |
| BR (2) | BRPI0722429A2 (hr) |
| CA (1) | CA2654334C (hr) |
| CY (1) | CY1112103T1 (hr) |
| DK (1) | DK2032551T3 (hr) |
| ES (1) | ES2371942T3 (hr) |
| HK (1) | HK1130052A1 (hr) |
| HR (1) | HRP20110845T1 (hr) |
| IL (1) | IL195676A (hr) |
| MX (1) | MX2008015754A (hr) |
| MY (1) | MY145788A (hr) |
| NO (2) | NO341508B1 (hr) |
| NZ (1) | NZ573706A (hr) |
| PL (1) | PL2032551T3 (hr) |
| PT (1) | PT2032551E (hr) |
| RS (1) | RS52034B (hr) |
| RU (2) | RU2444519C2 (hr) |
| SG (1) | SG174830A1 (hr) |
| SI (1) | SI2032551T1 (hr) |
| TW (2) | TWI373469B (hr) |
| UA (1) | UA97369C2 (hr) |
| WO (1) | WO2007144423A1 (hr) |
| ZA (1) | ZA200810315B (hr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS52343B (en) | 2007-12-20 | 2012-12-31 | Pharma Mar S.A. | ANTITUMOR UNITS |
| MX2010008922A (es) | 2008-02-20 | 2010-09-07 | Actelion Pharmaceuticals Ltd | Compuestos antibioticos azatriciclicos. |
| BRPI0908208A2 (pt) | 2008-02-22 | 2015-08-25 | Actelion Pharmaceuticals Ltd | Composto derivado de oxazolidinona, medicamento, composição farmacêutica que o contém e uso desse composto. |
| CN104151316B (zh) | 2008-10-07 | 2016-06-15 | 埃科特莱茵药品有限公司 | 三环噁唑烷酮抗生素化合物 |
| ES2628091T3 (es) | 2008-10-10 | 2017-08-01 | Idorsia Pharmaceuticals Ltd | Antibióticos de oxazolidinilo |
| WO2010149688A2 (en) | 2009-06-24 | 2010-12-29 | Pharma Mar, S.A. | Antitumoral compounds |
| GB201309807D0 (en) * | 2013-05-31 | 2013-07-17 | Pharma Mar Sau | Antibody drug conjugates |
| CN108467378A (zh) * | 2017-02-23 | 2018-08-31 | 复旦大学 | 一种二氢吡喃酮类化合物及其制备方法和用途 |
| JOP20190254A1 (ar) | 2017-04-27 | 2019-10-27 | Pharma Mar Sa | مركبات مضادة للأورام |
| CN110790737B (zh) * | 2019-11-07 | 2022-07-22 | 河南中烟工业有限责任公司 | 一种2,3-二氢-3,5-二羟基-6-乙基-4h-吡喃-4-酮的制备方法 |
| AU2022369058A1 (en) | 2021-10-22 | 2024-05-02 | Pharma Mar, S.A. | Antitumoral compounds |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA938019B (en) * | 1992-11-13 | 1995-04-28 | Upjohn Co | Pyran-2-ones and 5,6-dihydropyran-2-ones useful for treating HIV and other retroviruses |
| JP3684426B2 (ja) * | 1993-11-19 | 2005-08-17 | パーク・デイビス・アンド・カンパニー | プロテアーゼ阻害剤および抗ウイルス剤としての５，６−ジヒドロピロン誘導体 |
| US7446196B2 (en) * | 2004-06-03 | 2008-11-04 | Kosan Biosciences, Incorporated | Leptomycin compounds |
-
2007
- 2007-06-15 CN CN2011102036625A patent/CN102336730A/zh active Pending
- 2007-06-15 EP EP11177479A patent/EP2404913A3/en not_active Withdrawn
- 2007-06-15 AT AT07765445T patent/ATE522514T1/de active
- 2007-06-15 SG SG2011067998A patent/SG174830A1/en unknown
- 2007-06-15 RU RU2009101150/04A patent/RU2444519C2/ru active
- 2007-06-15 PT PT07765445T patent/PT2032551E/pt unknown
- 2007-06-15 MX MX2008015754A patent/MX2008015754A/es active IP Right Grant
- 2007-06-15 BR BRPI0722429-0A patent/BRPI0722429A2/pt not_active IP Right Cessation
- 2007-06-15 KR KR1020097000830A patent/KR101474031B1/ko active IP Right Grant
- 2007-06-15 EP EP07765445A patent/EP2032551B9/en active Active
- 2007-06-15 DK DK07765445.7T patent/DK2032551T3/da active
- 2007-06-15 WO PCT/EP2007/055959 patent/WO2007144423A1/en active Application Filing
- 2007-06-15 BR BRPI0713031A patent/BRPI0713031B8/pt active IP Right Grant
- 2007-06-15 UA UAA200900292A patent/UA97369C2/ru unknown
- 2007-06-15 AU AU2007259257A patent/AU2007259257B8/en active Active
- 2007-06-15 SI SI200730781T patent/SI2032551T1/sl unknown
- 2007-06-15 US US12/304,123 patent/US8324406B2/en active Active
- 2007-06-15 CA CA2654334A patent/CA2654334C/en active Active
- 2007-06-15 PL PL07765445T patent/PL2032551T3/pl unknown
- 2007-06-15 EP EP11177474A patent/EP2404912A3/en not_active Withdrawn
- 2007-06-15 CN CN2007800222645A patent/CN101679340B/zh active Active
- 2007-06-15 RS RS20110495A patent/RS52034B/en unknown
- 2007-06-15 JP JP2009514811A patent/JP5117491B2/ja active Active
- 2007-06-15 ES ES07765445T patent/ES2371942T3/es active Active
- 2007-06-15 NZ NZ573706A patent/NZ573706A/en unknown
- 2007-06-15 MY MYPI20085040A patent/MY145788A/en unknown
- 2007-06-19 AR ARP070102670A patent/AR061506A1/es active IP Right Grant
- 2007-06-20 TW TW096122071A patent/TWI373469B/zh active
- 2007-06-20 TW TW100146802A patent/TW201213316A/zh unknown
-
2008
- 2008-12-02 IL IL195676A patent/IL195676A/en active IP Right Grant
- 2008-12-04 ZA ZA2008/10315A patent/ZA200810315B/en unknown
-
2009
- 2009-01-06 NO NO20090054A patent/NO341508B1/no unknown
- 2009-09-03 HK HK09108044.0A patent/HK1130052A1/xx unknown
-
2011
- 2011-06-29 US US13/171,567 patent/US8501968B2/en active Active
- 2011-08-05 RU RU2011133128/04A patent/RU2011133128A/ru not_active Application Discontinuation
- 2011-09-14 NO NO20111248A patent/NO20111248L/no not_active Application Discontinuation
- 2011-10-05 JP JP2011220925A patent/JP2012021023A/ja active Pending
- 2011-11-14 HR HR20110845T patent/HRP20110845T1/hr unknown
- 2011-11-30 CY CY20111101175T patent/CY1112103T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110845T1 (hr) | Antitumorski dihidropiran-2-onski spojevi | |
| HRP20130942T1 (hr) | Aminodiazepini kao modulatori toll-u sliäśnih receptora | |
| AR080878A1 (es) | Derivados heterociclicos de ariletinilo, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos en el tratamiento de la esquizofrenia y trastornos cognitivos. | |
| JP2009504764A5 (hr) | ||
| HRP20160852T1 (hr) | Biciklični heterociklični spojevi kao inhibitori protein tirozin kinaze | |
| ATE427949T1 (de) | 4-a4-(5-oxo-2,3,5,11a-tetrahydro-5h-pyrrolo a2, 1-cua1,4ubenzodiazepin-8-yloxy)-butyrylaminou-1 - pyrrol-2-carbonsaurealkylesterderivate und verwandte verbindung zur behandlung einer proliferativen erkrankung | |
| JP2015537020A5 (hr) | ||
| AR036874A1 (es) | Derivados de fenetanolina, procedimiento de preparacion, uso en la fabricacion de medicamentos para enfermedades respiratorias | |
| RU2006146215A (ru) | Производные аминопропанола | |
| AR069490A1 (es) | Agonistas de los receptores de glucocorticoides | |
| EA200870196A1 (ru) | Индолсульфонамидные модуляторы рецепторов прогестерона | |
| EA200970928A1 (ru) | Антагонисты рецептора гонадотропин-рилизин-фактора и способы их применения | |
| RU2007125660A (ru) | Фенилпиперазиновые производные с сочетанием свойств неполного агонизма к рецепторам дофамина-d2 и ингибирования повторного поглощения серотонина | |
| ATE484502T1 (de) | Neue verbindungen | |
| HRP20120464T1 (hr) | Antitumorski spojevi | |
| JP2009539943A5 (hr) | ||
| EA200970704A1 (ru) | ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ АНТАГОНИСТЫ NK1 РЕЦЕПТОРА И БЛОКАТОРЫ Na КАНАЛОВ | |
| EA201270266A1 (ru) | Гетероциклические соединения | |
| PE20081703A1 (es) | Nuevos derivados triciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| RS54780B1 (sr) | Antikancerski steroidni laktoni nezasićeni na poziciji 7(8) | |
| WO2006002802A8 (en) | Phenyl derivatives comprising an acetylene group | |
| RU2014131017A (ru) | Хиназолиноновые производные в качестве ингибиторов hcv | |
| ATE432262T1 (de) | Pyrazolphenylderivate als ppar-aktivatoren | |
| AR065724A1 (es) | Macrolidos | |
| RU2008128816A (ru) | Противоопухолевые соединения |